For Quick Alerts
For Daily Alerts

AstraZeneca Shares Hit Upper Circuit on New Drug Launch


Shares of AstraZeneca hit upper circuit in the trade after the company announced that that it has launched FORXIGA, a breakthrough treatment for Type 2 diabetes mellitus.

The shares of the company were sen trading at Rs 1147 higher by 20 per cent on BSE.

Also read: What are circuit filters and how do they work?

AstraZeneca Shares Hit Upper Circuit on New Drug Launch
AstraZeneca Pharma India: Quotes, News
BSE 1774.20BSE Quote41.8 (2.36%)
NSE 1766.30NSE Quote29.85 (1.69%)

FORXIGA belongs to a new class of Type 2 diabetes mellitus medication-a highly selective inhibitor of sodium-glucose cotransporter 2 (SGLT2), the company said in the BSE filing.

It has a unique insulin independent mode of action that helps remove excess glucose from the body via urine which is associated with reductions in glycated haemoglobin (HbA1c), weight and systolic blood pressure, added further.

Globally, FORXIGA is the first medicine in the new SGLT2 inhibitor class to gain regulatory approval for the treatment of Type 2 diabetes mellitus.

AstraZeneca is a global, innovation-driven biopharmaceutical business that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of cardiovascular, metabolic, respiratory, inflammation, autoimmune, oncology, infection and neuroscience diseases.

Read more about: astrazeneca
Company Search
We use cookies to ensure that we give you the best experience on our website. This includes cookies from third party social media websites and ad networks. Such third party cookies may track your use on Goodreturns sites for better rendering. Our partners use cookies to ensure we show you advertising that is relevant to you. If you continue without changing your settings, we'll assume that you are happy to receive all cookies on Goodreturns website. However, you can change your cookie settings at any time. Learn more